Condition: Multiple Myeloma (MM) · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.
This description comes directly from the study's public registry record.
Elena Zamagni, MD, PhD · +39 051 214 3680 · e.zamagni@unibo.it
Always discuss trial participation with your own doctor first.
| Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS | Meldola, Forlì-Cesena, Italy | Not Yet Recruiting |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Italy | Recruiting |
| ARNAS "G. Brotzu" di Cagliari | Cagliari, Italy | Not Yet Recruiting |
| Azienda Ospedaliera Universitaria Federico II | Naples, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06767254